The European Commission has approved a new intravenous formulation of Ultomiris (ravulizumab) to treat for adults and children with…
Articles by Joana Carvalho, PhD
The U.S. Food and Drug Administration (FDA) has approved a new formulation of Ultomiris (ravulizumab), a treatment…
Ultomiris (ravulizumab) has been approved in Japan for the treatment of adults and children with atypical…
The aHUS Alliance Global Action estimates there could be 84,000 people living with atypical hemolytic uremic syndrome (aHUS)…
Mutations leading to the overactivation of the complement regulator protein C3 should be recognized as a cause of…
Ultomiris (ravulizumab-cwvz) is safe and effective at resolving acute and life-threatening complications of atypical hemolytic uremic syndrome…
A medication for high blood pressure, Tekturna (aliskiren) may be used as an add-on therapy to manage hypertension associated with…
Understanding the disease-related alterations in a large gene cluster that lead to atypical hemolytic uremic syndrome (aHUS) may help…
Experts in South Korea have proposed a set of new diagnostic criteria to distinguish thrombotic microangiopathy associated with…
The U.S. Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvz) for the treatment…